Table 2.
Clinicopathological features associated with HPD in NSCLC patients.
| Study | Incidence | Risk factors | Ref |
|---|---|---|---|
| Yan Chen et al | 8.02 to 30.43% (1389) |
ECOG> 1, RMH score≥ 2, serum LDH level > ULN, the number of metastasis sites > 2, and liver metastasis |
(35) |
| Yong Jun Choi et al | 19.2% (15/78) | age, size of tumor and number of various metastatic lesions | (36) |
| Lee X Li et al | 119/3129 | elevated NLR | (37) |
| Youjin Kim et al | / | dNLR > 4 and LDH level > ULN | (16) |
| Jehun Kim et al | 15.9%(35/219) | PD-L1 expression < 50%, metastatic sites≥ 3 NLR ≥ 3.3, and hemoglobin level < 10 |
(38) |
| Seo Ree Kim et al | 11.3% (26/231) | heavy smoker, very low PD-L1 expression, multiple metastasis, and CAR index, | (39) |
| M P Petrova et al | 4.8%(8/167) | a high pre-immunotherapy NLR2 and the presence of sarcopenia | (40) |
| Kristin L Ayers et al | / | African American patient group had lower incidence (14.7%) of HPD than the White patient group (24.5%). | (41) |
ECOG, Eastern Cooperative Oncology Group; RMH score, Royal Marsden Hospital score; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; ULN, upper limit of normal; LDH, lactate dehydrogenase; STK11, serine/threonine kinase 11 gene; ctDNA, circulating tumor DNA.